Oral semaglutide could benefit high-risk patients with Type 2 diabetes

Oral semaglutide may reduce the risk of major adverse cardiovascular events among patients with Type 2 diabetes who have a history of cardiovascular or kidney disease.

In a study published in The New England Journal of Medicine, researchers randomly assigned nearly 10,000 patients aged 50 years or older who had Type 2 diabetes as well as atherosclerotic cardiovascular disease, chronic kidney disease or both comorbidities to receive either 14 milligrams of oral semaglutide or placebo per day.

The researchers found that a lower proportion of the patients in the oral semaglutide group experienced major adverse cardiovascular events compared with those in the placebo group. They reported no statistically significant increase in the incidence of serious adverse events following the use of oral semaglutide.

Read more: The New England Journal of Medicine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.